Get started
Author

Andrea S. Fung

ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results
2023 · Valsamo Anagnostou, Cheryl Ho, et al. · Nature Medicine · 171
PDF
Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial
2024 · Marcin Dzienis, Juan Cundom, et al. · Journal of Clinical Oncology · 59
PDF
Concurrent and Sequential Administration of Chemotherapy and the Mammalian Target of Rapamycin Inhibitor Temsirolimus in Human Cancer Cells and Xenografts
2009 · Andrea S. Fung, Licun Wu, et al. · Clinical Cancer Research · 59
The effect of chemotherapeutic agents on tumor vasculature in subcutaneous and orthotopic human tumor xenografts
2015 · Andrea S Fung, Carol Lee, et al. · BMC Cancer · 49
PDF
A Real-World Evaluation of Atezolizumab Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC in Canada
2021 · Anifat A. Elegbede, Amanda J. Gibson, et al. · JTO Clinical and Research Reports · 36
Use of Molecular Biomarkers to Quantify the Spatial Distribution of Effects of Anticancer Drugs in Solid Tumors
2013 · Jasdeep K. Saggar, Andrea S. Fung, et al. · Molecular Cancer Therapeutics · 30
Quantitative Immunohistochemistry for Evaluating the Distribution of Ki67 and Other Biomarkers in Tumor Sections and Use of the Method to Study Repopulation in Xenografts after Treatment with Paclitaxel
2012 · Andrea S. Fung, James Jonkman, et al. · Neoplasia · 30
PDF
A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors
2021 · Adi Kartolo, Harriet Feilotter, et al. · Cancer Treatment and Research Communications · 27
PDF
Second‐line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real‐world eligibility for cabozantinib, regorafenib, and ramucirumab
2020 · Andrea S. Fung, Vincent C. Tam, et al. · Cancer Medicine · 26
PDF
Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer
2022 · Shelley Kuang, Andrea S. Fung, et al. · Current Oncology · 23
PDF
A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer
2021 · A.S. Fung, D.M. Graham, et al. · Lung Cancer · 15
Assessment Of Tumour Infiltrating Lymphocytes And Pd-l1 Expression In Adenoid Cystic Carcinoma Of The Salivary Gland
2021 · Wenqian Chen, Andrea S. Fung, et al. · Clinical and investigative medicine · 14
PDF
Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients
2021 · on behalf of the LACE-Bio Collaborative Group, Andrea S. Fung, et al. · Translational Lung Cancer Research · 12
PDF
PD-L1 assessment in cytology samples predicts treatment response to checkpoint inhibitors in NSCLC
2022 · Sally C.M. Lau, Madhumitha Rabindranath, et al. · Lung Cancer · 9
Outcomes of Hypofractionated Stereotactic Radiotherapy for Small and Moderate-Sized Brain Metastases: A Single-Institution Analysis
2022 · Michael Yan, Osbert Zalay, et al. · Frontiers in Oncology · 9
PDF
CXCR4 expression in lung carcinogenesis: Evaluating gender-specific differences in survival outcomes based on CXCR4 expression in early stage non-small cell lung cancer patients
2021 · Andrea S. Fung, Karen Kopciuk, et al. · PLoS ONE · 9
PDF
Real world eligibility for cabozantinib (C), regorafenib (Reg), and ramucirumab (Ram) in hepatocellular carcinoma (HCC) patients after sorafenib (S).
2019 · Andrea S. Fung, Vincent C. Tam, et al. · Journal of Clinical Oncology · 9
Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies
2023 · Sally C.M. Lau, Kirstin Perdrizet, et al. · JTO Clinical and Research Reports · 6
PDF
Combination Intravenous Immune Globulin (IVIG) and High Dose Steroids for Treatment of Immune-Related Myelitis in a Non-Small Cell Lung Cancer Patient Treated With Pembrolizumab and Palliative Radiation Treatment: A Case Report
2022 · Timothy Owen, Andrea S. Fung · Clinical Lung Cancer · 6
Complete Response and Survival Outcomes in Patients with Advanced Cancer on Immune Checkpoint Inhibitors
2022 · Adi Kartolo, Cynthia Yeung, et al. · Immunotherapy · 6
An Assessment of Extended Pembrolizumab Dosing in Advanced Non-Small-Cell Lung Cancer in the Covid-19 Pandemic
2023 · Gordon Taylor Moffat, Lilian Hanna, et al. · Immunotherapy · 5
PDF
Scheduling of paclitaxel and gefitinib to inhibit repopulation for optimal treatment of human cancer cells and xenografts that overexpress the epidermal growth factor receptor
2013 · Andrea S. Fung, Man Yu, et al. · Cancer Chemotherapy and Pharmacology · 5
Effects of cannabinoids on immune checkpoint inhibitor response: CCTG pooled analysis of individual patient data
2025 · Courtney H. Coschi, Keyue Ding, et al. · Immunotherapy · 3
PDF
Brief Report: Real-World Eligibility for Clinical Trials in Patients With Extensive-Stage SCLC at a Tertiary Care Center
2024 · Navdeep Dehar, Mahbuba Meem, et al. · JTO Clinical and Research Reports · 3
PDF
Abstract CT253: Results from KEYNOTE-B99: Phase 2 study of first-line (1L) pembrolizumab (pembro) plus investigational agents and chemotherapy (chemo) for extensive-stage small-cell lung cancer (ES-SCLC)
2024 · Delvys Rodríguez-Abreu, Maximillian Hochmair, et al. · Cancer Research · 3
Works count: 60
Citation count: 650
H-index: 12
I10-index: 13
Year
Topic
Type